Shearman & Sterling represented International Chemical Investors Group (ICIG) on the potential acquisition of the pharmaceutical ingredients activities of Tessenderlo Group, which Tesssenderlo intends to sell subject to necessary employee consultation procedures. The acquisition would include two production sites: Farchemia (in Italy) and Calaire Chimie (in France).
ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. With a total sale of approximately €700 million, ICIG companies operate 17 manufacturing facilities in Europe and the United States with more than 3,300 employees. Since 2004, ICIG has acquired 17 businesses, all of which have origins in major global chemical or pharmaceutical corporations and are independently managed.
Shearman & Sterling advised ICIG on numerous transactions, particularly in Germany, France and Italy, including in the acquisition of pharmaceutical intermediates businesses from Genzyme and Roche, the acquisition of the fine chemical and other brominated products business (Port-de-Bouc/France) from Albemarle, the acquisition of a facility in Latina (Italy) from Bristol Myers Squibb, the acquisition of Enka from Acordis Beheer, and the sale of all shares in CarboTech Engineering to Schmack Biogas.
The Shearman & Sterling team advising ICIG on the transaction included partners Thomas König (Frankfurt-Mergers & Acquisitions), Nicolas Bombrun (Paris-Mergers & Acquisitions), Bodo Bender (Frankfurt-Tax) andNiels Dejean (Paris-Tax) ; counsel Tommaso Tosi (Milan-Mergers & Acquisitions), Joachim Grittmann (Frankfurt-Public Law), and Mathias Stöcker (Brussels/Düsseldorf-Antitrust); and associates Andreas Löhdefink, Peter Breschendorf, Boris Häfele (all Frankfurt-Mergers & Acquisitions), Kolja Stehl (Frankfurt-Finance), Barbara Le Chapellier (Paris-Mergers & Acquisitions), Armelle Sandrin-Deforge (Paris-Mergers & Acquisitions/Environmental), Clemens York (Brussels-Antitrust) and Marco Barbi (Milan-Capital Markets).
